- Cool Tool – The Human Protein AtlasPosted 6 days ago
- Optimization of Roche Liberase MNP-S GMP Grade in the Enzymatic Digestion of Human Umbilical Cord for the Isolation of Mesenchymal Stem CellsPosted 7 days ago
- Ask the Expert – Maximizing Transient Protein ProductionPosted 1 week ago
- Enabling Viral Vector Production and Vaccine Manufacturing using the iCELLis – a single-use, automated, and closed manufacturing platformPosted 2 weeks ago
- Cell Culture Basics – Mycoplasma 101 – A practical guide to prevention, detection and elimination of mycoplasma contaminationPosted 3 weeks ago
- Going to BPI West 2017? Don’t miss these great talks and activities!Posted 4 weeks ago
- Cool Tool – PRIME-XV® T Cell CDM – First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 4 weeks ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 1 month ago
- Continuous Processing Optimization with Smarter ToolsPosted 1 month ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 1 month ago
Achieve gram per liter protein yields in a transient CHO system
CHO cells are the predominant host for biotherapeutic protein expression, with roughly 70% of licensed biologics manufactured in CHO. Multiple attributes make CHO cells desirable for bioproduction including the ability to adapt to high-density suspension culture in serum-free and chemically-defined media and the incorporation of post-translational modifications that are biologically-active in humans. For these reasons, the ability to produce transient CHO-derived proteins early on during drug development is highly advantageous to minimize, as much as possible, changes in protein quality/function observed when moving from R&D to bioproduction. Unfortunately, CHO cells express lower levels of protein than HEK293 cells in existing transient systems, in some instances 50-100 times less than the best 293-based systems. The recent introduction of the ExpiCHO transient expression system allows for unprecedented access to CHO-derived proteins early on during candidate selection and may serve to revolutionize the use of CHO cells for transient protein expression during the drug development process.
This Ask the Expert session is sponsored by Thermo Fisher Scientific, Inc and is hosted by Jonathan Zmuda, Ph.D., Associate Director of Cell Biology in the Life Sciences Solutions Group. Prominent among his roles, Dr. Zmuda leads a team dedicated to discovering and developing new technologies and products useful for cell biology applications including protein expression, cell culture, rare cell analysis and instrumentation. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.
Who should visit the session?
- Do you need a high-expressing transient CHO expression system for your work?
- Do you use 293 cells for drug candidate transient expression due to low levels of protein produced in transient CHO systems, even though your drug candidates will eventually be produced in CHO cells?
- Are post-translational modifications of proteins critical to your work?
- Do you encounter hard to express proteins that do not express well in 293 cells and would like another option to improve your protein titers?
If so, please take advantage of the opportunity to ask our expert a question and participate in a lively discussion on transient CHO expression.